The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Evolv Technologies Holdings, Inc. | COM CL A | 30049H102 | 47,051,023 | 9,681,280 | SH | SOLE | 9,681,280 | 0 | 0 | ||
Mind Medicine (MindMed) Inc. | COM NEW | 60255C885 | 314,095 | 100,349 | SH | SOLE | 100,349 | 0 | 0 | ||
Recursion Pharmaceuticals, Inc. | CL A | 75629V104 | 45,449,568 | 5,941,120 | SH | SOLE | 5,941,120 | 0 | 0 | ||
Rocket Lab USA, Inc. | COM | 773122106 | 12,830,553 | 2,929,350 | SH | SOLE | 2,929,350 | 0 | 0 | ||
Roivant Sciences Ltd. | SHS | G76279101 | 45,260 | 3,875 | SH | SOLE | 3,875 | 0 | 0 |